The European Medicines Agency will review GSK's request to approve its asthma drug Nucala as an additional treatment for ...

Nucala (mepolizumab) and Dupixent (dupilumab) are brand-name subcutaneous injections. They’re both prescribed for asthma and chronic rhinosinusitis with nasal polyps. Each drug may also be ...

GSK’s application is underpinned by the positive outcomes from the Phase III MATINEE trial, which demonstrated a significant ...

Nucala isn’t known to interact with drugs, supplements, or alcohol. However, Nucala may cause certain vaccines to be less effective. Talk with your doctor to help avoid potentially harmful ...

GSK’s share price has fallen a long way from its one-year high, which has only increased the major undervaluation I'd seen in the stock before that. The post GSK’s share price looks a steal to me ...

GSK said on Monday that the European Medicines Agency has accepted its application to expand the use of ‘Nucala’, or ...

GSK plc GSK announced that the European Medicines Agency (“EMA”) has accepted for review a regulatory filing, seeking approval for a new indication of its respiratory drug, Nucala (mepolizumab).

Nucala (mepolizumab) is a prescription injection used to treat a type of asthma and other inflammatory conditions. Nucala isn’t known to interact with other drugs, alcohol, or supplements.

March 24 (Reuters) - The European Medicines Agency will review GSK's (GSK.L), opens new tab request to approve its asthma drug Nucala as an additional treatment for chronic obstructive pulmonary ...

GSK on Monday said that the European Medicines Agency has agreed to review a request to approve the British drugmaker's ...

GSK (GSK) plc announced that the European Medicines Agency has accepted for review its application to expand the use of Nucala, a monoclonal ...